“And in oncology, we now expect Imbruvica global revenues of $2.9 billion, an increase of $100 million, reflecting higher persistency rates for existing patients and Venclexta global sales of $2.8 billion, an increase of $100 million, reflecting continued strong demand in CLL.”

In context

“llion. This reflects a relatively neutral impact from foreign exchange on full year sales growth. Our updated revenue forecast includes the following approximate assumptions for several of our key products and therapeutic areas. In Immunology, we now expect Skyrizi global revenues of $17.1 billion, an increase of $600 million, reflecting continued share gains in psoriasis and IBD and U.S. HUMIRA revenues of $3 billion, a decrease of $500 million, reflecting biosimilar competition. In neuroscience, we now expect global sales of $10.5 billion, an increase of $300 million. This includes a $100 million increase for VYALEV, reflecting strong international uptake with the remaining $200 million increase split relatively evenly across Vraylar, BOTOX Therapeutic and the total oral CGRP portfolio. And in oncology, we now expect Imbruvica global revenues of $2.9 billion, an increase of $100 million, reflecting higher persistency rates for existing patients and Venclexta global sales of $2.8 billion, an increase of $100 million, reflecting continued strong demand in CLL. Moving to the P&L for 2025. We continue to forecast full year adjusted gross margin of approximately 84% of sales. We now expect adjusted R&D expense of approximately $9 million and adjusted SG&A expense of approximately $13.5 billion. We also now anticipate an adjusted operating margin ratio of roughly 45% of sales, in line with our previous expectations after including the 1.8% unfavorable impact of acquired IPR&D expense incurred through the second quarter. Turning to the third quarter. We anticipate net revenues of approximately $15.5 billion. This reflects an estimated 1% favorable impact from foreign exchange on sales growth. We expect adjusted earnings per share between $3.24 and $3.28. This guidance does not include acquired IPR&D expense that may be incurred in the quarter. In cl”